Efficacy and immune-related adverse event associations in avelumab-treated patients

BACKGROUND: Adverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. We analyzed patients treated with avelumab from the JAVELIN Solid Tumor and M...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Kelly, Karen, Manitz, Juliane, Patel, Manish R, D’Angelo, Sandra P, Apolo, Andrea B, Rajan, Arun, Kasturi, Vijay, Speit, Isabell, Bajars, Marcis, Warth, John, Gulley, James L
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Clinical/Translational Cancer Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7682456/
https://ncbi.nlm.nih.gov/pubmed/33219092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001427
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi